deltatrials
Terminated PHASE2 INTERVENTIONAL 4-arm NCT03248492

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1 (DESTINY-Breast01)

Sponsor: AstraZeneca

Conditions Breast Cancer
Interventions DS-8201a
Updated 29 times since 2017 Last updated: Jun 9, 2025 Started: Aug 25, 2017 Primary completion: Mar 21, 2019 Completion: May 6, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The last participant was transitioned to alternative study.

Other terminated trials from AstraZeneca

See all terminations from AstraZeneca

Other Breast Cancer trials with similar outcome

Browse all Breast Cancer trials

Listed as NCT03248492, this PHASE2 trial focuses on Breast Cancer and remains terminated or withdrawn. Sponsored by AstraZeneca, it has been updated 29 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Aug 2019 · 5 months · monthly snapshot~Aug 2019 – ~Mar 2020 · 7 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Sep 2020 · 5 months · monthly snapshot~Sep 2020 – ~Dec 2020 · 3 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Nov 2021 · 5 months · monthly snapshot~Nov 2021 – ~Nov 2022 · 12 months · monthly snapshot~Nov 2022 – ~Dec 2023 · 13 months · monthly snapshot~Dec 2023 – ~Mar 2024 · 3 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jul 2025 · 9 months · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

29 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Jul 2025 — Sep 2025 [monthly]

    Terminated PHASE2

    Status: Completed → Terminated

  3. Oct 2024 — Jul 2025 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 24 earlier versions

  1. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Dec 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Nov 2022 — Dec 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Nov 2021 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Jun 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Sep 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2

  9. Apr 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE2

  10. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2

  11. Aug 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2

  12. Mar 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE2

  13. Jan 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  14. Oct 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  15. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  16. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  17. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  18. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  19. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  20. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE2

  21. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE2

  22. Dec 2017 — Feb 2018 [monthly]

    Recruiting PHASE2

  23. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  24. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

    First recorded

Aug 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Daiichi Sankyo
  • Daiichi Sankyo Co., Ltd.
Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Japan , Anchorage, United States , Atlanta, United States , Avignon, France , Badajoz, Spain , Barcelona, Spain , Baytown, United States , Besançon, France , Boca Raton, United States , Bonheiden, Belgium and 68 more locations